Recent News

• 11.04.2025 - Cumberland Pharmaceuticals 2025 Q3 earnings call
• 10.01.2025 - CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
• 09.29.2025 - TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
• 08.05.2025 - Cumberland Pharmaceuticals 2025 Q2 earnings call
• 08.05.2025 - Cumberland Pharmaceuticals 2025 Q2 earnings call
• 08.05.2025 - Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
• 08.04.2025 - CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
• 07.29.2025 - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Recent Filings

• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - 8-K Current report